Evidence map›Paper›PMID 42324267›Full record

Trial reportScientific reports2026

One-year impact on HPV vaccination coverage of a school- and primary care-based intervention: the PrevHPV cluster randomised trial.

Aurélie Bocquier, Morgane Michel, Judith E Mueller, Maïa Simon, Amandine Gagneux-Brunon, Aurélie Gauchet, Serge Gilberg, Anne-Sophie Le Duc-Banaszuk, Sébastien Bruel, Bruno Giraudeau and 2 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04945655 (Impact of a School- and Primary Care-based Multicomponent Intervention on HPV Vaccination Acceptability Among French Adolescents), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04945655 nacompletednot on this map

Impact of a School- and Primary Care-based Multicomponent Intervention on HPV Vaccination Acceptability Among French Adolescents: a Cluster Randomized Controlled Trial

TypeinterventionalSponsorInstitut National de la Santé Et de la Recherche Médicale, FranceRan2021 to 2023Enrolled30,739ConditionsHPV Vaccine AcceptabilityArmsAdolescents and parents' education and motivation at school (component 1), General practitioners' training (component 2), Access to vaccination at school (component 3)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Aurélie Bocquier *Université de Lorraine, Inserm, INSPIIRE, 54000, Nancy, France. aurelie.bocquier@univ-lorraine.fr.
Morgane Michel *ECEVE, UMR 1123, Inserm, Université Paris Cité, 75010, Paris, France.
Judith E MuellerUnité d'Epidémiologie des Maladies Emergentes, Institut Pasteur, Université Paris Cité, 75015, Paris, France.
Maïa SimonUniversité de Lorraine, Inserm, INSPIIRE, 54000, Nancy, France.
Amandine Gagneux-BrunonCIC 1408, Inserm, CHU de Saint-Etienne, Université de Saint-Etienne, 42000, Saint Etienne, France.
Aurélie GauchetLIP/PC2S, Université Savoie Mont Blanc, Université Grenoble Alpes, 38000, Grenoble, France.
Serge GilbergDépartement de Médecine Générale, Université Paris Cité, 75014, Paris, France.
Anne-Sophie Le Duc-BanaszukCentre Régional de Coordination des Dépistages des cancers-Pays de la Loire, 49000, Angers, France.
Sébastien BruelCIC 1408, Inserm, CHU de Saint-Etienne, Université de Saint-Etienne, 42000, Saint Etienne, France.
Bruno GiraudeauSPHERE U1246, Inserm, Université de Tours, Université de Nantes, 37044, Tours, France.
Nathalie ThillyUniversité de Lorraine, Inserm, INSPIIRE, 54000, Nancy, France.
PrevHPV Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human papillomavirus (HPV) vaccine coverage (VC) remains suboptimal in many countries. The PrevHPV national research programme aimed to codevelop and evaluate a three-component intervention including: 'education and motivation' of adolescents, 'at-school vaccination', 'general practitioners (GPs)' training'. We assessed its impact on VC at one year through a cluster randomized trial (July 2021-April 2022) conducted in French municipalities (clusters) receiving 0, 1, 2, or 3 components. The outcomes (≥ 1-dose and full HPV VC at one year among 11-14-year-olds) were estimated using data from the national health reimbursement database and data collected during the trial. We performed intention-to-treat and post-hoc analysis adjusted for the dose of intervention using cluster-level linear models. Ninety-one municipalities were included. 'At-school vaccination' significantly increased ≥ 1-dose VC, in both intention-to-treat (+ 2.85 percentage points (pp), 95%CI = 0.62 to 5.09) and post-hoc analysis (+ 4.60 pp, 95%CI = 1.79 to 7.41). No significant effects were found for the other components. Results were similar for full VC. 'At-school vaccination' significantly increased VC only in municipalities with the lowest access to GPs. School-based vaccination was effective in increasing HPV VC in the medium term and may reduce VC healthcare access-driven territorial disparities. Challenges remain in parental engagement and consent for vaccination at school.Trial registration: Clinicaltrials.gov, NCT04945655. Registered 30 June 2021.

Indexed as

Human Papillomavirus VirusesPapillomavirus InfectionsPapillomavirus VaccinesVaccination CoverageAdolescentChildFemaleFranceHumansMalePrimary Health CareSchoolsVaccinationPapillomavirus VaccinesEffectivenessGeneral practitionersHuman papillomavirusSchool-based immunization programmes

Identifiers

PMID42324267
PMCPMC13572500

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.